Home › Research › Treatments
Aldehyde-Mediated Neurotoxicity and Lutein Intervention: A Novel Therapeutic Strategy for Alzheimer's Disease
Prakash Sarwade1, Kavita Gaisamudre*2, Kalpana Sonwani3, Khushboo Jasra4, Khushi Rawat5, Purabi Saha6, Roshan Kumar7. Zenodo (CERN European Organization for Nuclear Research), 2026-01-19
Topic: Brain proteins, microglia and lab models
Alzheimer disease (AD) is a major health issue of global concern whereby there are minimal treatment options. The existing therapies, which have been recently added to the arsenal of disease-modifying anti-amyloid antibodies, provide limited clinical benefits but are characterized by a high cost and risk. This is one of the reasons why alternative approaches to address earlier, multifactorial causes of neurodegeneration are urgently required. Chronic oxidative stress is a central and early pathological alteration in AD that initiates lipid peroxidation and the production of extremely reactive and toxic α β-unsaturated aldehydes, including 4-hydroxynonenal (4-HNE) and acrolein. These aldehydes are direct mediators of neuronal injury and can result in covalent conjugates with proteins, mitochondrial dysfunction, and neuroinflammation and protein aggregation. The new, comprehensive hypothesis that has been suggested in this review is that the dietary carotenoid lutein is a high-affinity "molecular sponge" of these toxic aldehydes. In addition to its known antioxidant and anti-inflammatory effects, the conjugated polyene chain of lutein is postulated to react via a Michael addition reaction with electrophilic aldehydes, neutralizing them in the lipid-bi-layer, and avoiding their attack on other important cellular structures. We elaborate on the chemical logic of this interaction and synthesize preclinical evidence on in vitro and in vivo models of the ability of lutein to scavenge the aldehydes, reduce the pathological biomarkers, maintain the synaptic integrity and salvage the cognitive functioning. In addition, we comment on the pharmacokinetic difficulties of the brain delivery and present the future research directions, such as the formation of synthetic analogues, as well as the study of the role of lutein in the gut-brain axis. The potential to reduce the neuroprotective impact of AD in aldehyde toxicity cascade by targeting lutein is a good approach that is not only pleiotropic but also safer.
Key findings
- These aldehydes are direct mediators of neuronal injury and can result in covalent conjugates with proteins, mitochondrial dysfunction, and neuroinflammation and protein aggregation.
Why it matters
This review proposes that the dietary carotenoid lutein could act as a 'molecular sponge' neutralizing toxic aldehydes such as 4-HNE and acrolein that injure neurons. This is a hypothesis about a possible mechanism, not evidence that lutein treats, cures, or prevents Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 26 of the 64 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Zenodo (CERN European Organization for Nuclear Research)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 64 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 26 of the 64 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Sarwade1, P., Gaisamudre*2, K., Sonwani3, K., Jasra4, K., Rawat5, K., Saha6, P., et al. (2026). Aldehyde-Mediated Neurotoxicity and Lutein Intervention: A Novel Therapeutic Strategy for Alzheimer's Disease. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.18298037
Vancouver
Sarwade1 P, Gaisamudre*2 K, Sonwani3 K, Jasra4 K, Rawat5 K, Saha6 P, et al. Aldehyde-Mediated Neurotoxicity and Lutein Intervention: A Novel Therapeutic Strategy for Alzheimer's Disease. Zenodo (CERN European Organization for Nuclear Research). 2026. doi:10.5281/zenodo.18298037.
BibTeX
@article{sarwade2026-69c35085,
author = {Sarwade1, Prakash and Gaisamudre*2, Kavita and Sonwani3, Kalpana and Jasra4, Khushboo and Rawat5, Khushi and Saha6, Purabi and Kumar7, Roshan},
title = {{Aldehyde-Mediated Neurotoxicity and Lutein Intervention: A Novel Therapeutic Strategy for Alzheimer's Disease}},
journal = {Zenodo (CERN European Organization for Nuclear Research)},
year = {2026},
doi = {10.5281/zenodo.18298037},
url = {https://doi.org/10.5281/zenodo.18298037}
}
Related studies in Treatments
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.